Latest Teriparatide Stories

DENVER, Sept. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR). "These data enhance our understanding of why many women discontinue treatment with current osteoporosis therapies,...

Goal to extend useful life of arthritic knees and hipsAn existing osteoporosis drug is the first ever found to prevent cartilage loss from osteoarthritis following injury to a joint, and may also regenerate some cartilage that has been lost to osteoarthritis, according to an early study presented today at the annual meeting of the American Society for Bone and Mineral Research in Denver. While the study was in mice, the model closely mimics human osteoarthritis that develops following knee...

Studies suggest that a first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments and could soon add a more expensive but easier option to the booming market, The Associated Press reported.Amgen Inc's genetically engineered denosumab only requires two shots a year and could be approved for sale this fall.Many osteoporosis patients stop taking other drugs due to side effects or frequent dosing. But doctors say denosumab's high cost may be a...

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Radius Health ("Radius") today announced topline Phase 2 data demonstrating that in women with osteoporosis, BA058 -- the company's novel PTHrP (parathyroid hormone-related protein) analog -- significantly increased bone mineral density (BMD) at the lumbar spine and femoral neck (a common fracture site located in the hip joint) after six months of therapy. The gains in lumbar spine and femoral neck BMD were further increased in a subset of patients...

INDIANAPOLIS, July 23 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved a new use for its osteoporosis drug FORTEO((R)) [teriparatide (rDNA origin) injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture. Glucocorticoid therapy is the most common cause of secondary osteoporosis, leading to bone loss and an increased risk for...

Bone fractures might heal faster if the patient is injected with medications. This is the outcome of a unique study of 102 women with wrist fractures.The study was led by Per Aspenberg, Professor of Orthopaedics at Linköping University."This is the first study in the world that shows that we can accelerate fracture healing in humans with medication, even without surgery. We measured how long it took before common wrist fractures healed and compared this with patients who received the...

Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen's novel agent denosumab and Eli Lilly's parathyroid hormone (PTH) analogue Forteo/Forsteo (teriparatide) will drive robust 4.3 percent annual growth in the osteoporosis drug market from 2013 to...

A drug approved for the treatment of osteoporosis is healing broken bones with stem cells.Since 2002, teriparatide (Forteo) has been used to treat osteoporosis, but scientists have discovered a new use for the drug in helping bones repair fractures -- particularly in bones that are otherwise difficult to heal. These findings could be especially beneficial for the elderly, those who suffer fractures of the pelvis, clavicle or vertebra, which have no viable treatments, and sick patients who...

In-body stem cell therapy has enormous potential for bone injuriesRarely will physicians use the word "miraculous" when discussing patient recoveries. But that's the very phrase orthopedic physicians and scientists are using in upstate New York to describe their emerging stem cell research that could have a profound impact on the treatment of bone injuries. Results from preliminary work being released today show patients confined to wheelchairs were able to walk or live...

COLLEGEVILLE, Pa., Feb. 19 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), today adopted a positive opinion recommending to grant a marketing authorization for CONBRIZA(TM) (bazedoxifene) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. CONBRIZA, an investigational medicine, is in development by Wyeth Pharmaceuticals, a division of Wyeth (NYSE:...